Centre Jean Perrin
Clermont-Ferrand, France
52 recruiting
Showing 1–20 of 72 trials
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled77 locationsNCT04585750
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled555 locationsNCT06492616
Recruiting
Phase 2
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
SeminomaStage II
Centre Leon Berard90 enrolled15 locationsNCT05529251
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled144 locationsNCT07213674
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Endometrial CancerRecurrent or Progressive Endometrial Cancer
Genmab660 enrolled120 locationsNCT07166094
Recruiting
Phase 2Phase 3
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Ovarian CarcinosarcomaEndometrial Carcinosarcoma
ARCAGY/ GINECO GROUP138 enrolled36 locationsNCT03651206
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled352 locationsNCT06065748
Recruiting
Not Applicable
COsegregation of VARiants in Panel of Genes
Genetic PredispositionGene Mutation-Related Cancer
Institut Curie11,000 enrolled62 locationsNCT01689584
Recruiting
Phase 3
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
Soft Tissue Sarcoma
Institut Claudius Regaud600 enrolled19 locationsNCT04307277
Recruiting
Phase 3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled150 locationsNCT07225946
Recruiting
Phase 2
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Biliary Tract Cancer
UNICANCER72 enrolled41 locationsNCT06529718
Recruiting
Phase 2
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals120 enrolled27 locationsNCT06769698
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer+1 more
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company2,295 enrolled211 locationsNCT05945732
Recruiting
Phase 3
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3K27-alteredDiffuse Midline Glioma, H3 K27M-Mutant
Gustave Roussy, Cancer Campus, Grand Paris433 enrolled50 locationsNCT05476939
Recruiting
Phase 1Phase 2
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Triple Negative Breast Cancer(TNBC)Colorectal Cancer (CRC)+6 more
Lumara Bio Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Phase 3
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Ovarian Cancer
ARCAGY/ GINECO GROUP250 enrolled72 locationsNCT06476184
Recruiting
Not Applicable
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Hepatocellular CarcinomaMetastatic Colorectal CancerNeuroendocrine Tumors+2 more
UNICANCER330 enrolled29 locationsNCT05443087
Recruiting
Phase 3
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
Squamous Cell Carcinoma of Head and Neck
UNICANCER102 enrolled26 locationsNCT04747054
Recruiting
Phase 3
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
Early Breast CancerPremenopausal Breast CancerHR+/HER2- Breast Cancer
UNICANCER3,380 enrolled105 locationsNCT07106632